ResearcherTufts Medical CenterNo recent work listed

Guo‐fu Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3175-5882; OpenAlex author ID A5057482532. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper

Papers 2

HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.01.011 ↗
Neamine inhibits growth of pancreatic cancer cells in vitro and in vivo. Co-author DOI 10.1007/s11596-016-1546-2 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ping Fan · 1 shared paper, 2019 · strength 0.11
- Paper HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer. DOI 10.1016/j.pan.2019.01.011 ↗
Xin Jin · 1 shared paper, 2019 · strength 0.11
- Paper HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer. DOI 10.1016/j.pan.2019.01.011 ↗
Yunxia Wu · 1 shared paper, 2016 · strength 0.08
- Paper Neamine inhibits growth of pancreatic cancer cells in vitro and in vivo. DOI 10.1007/s11596-016-1546-2 ↗
Ya-ping Liu · 1 shared paper, 2016 · strength 0.08
- Paper Neamine inhibits growth of pancreatic cancer cells in vitro and in vivo. DOI 10.1007/s11596-016-1546-2 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.